Eileen Dolan, PhD, with pipette
Cancer researcher M. Eileen Dolan, PhD, is a leader in the Clinical and Experimental Therapeutics Program.

Leadership

Program Leaders: M. Eileen Dolan, PhD, and Russell Szmulewitz, MD

The Clinical and Experimental Therapeutics Program is a cohesive, integrated program with a long-standing focus on drug development at all phases of clinical testing and a strong pharmacogenomics component. The program fosters interaction between basic and clinical scientists for the development of innovative and effective therapies.

Key Research Themes

  • Conduct pharmacogenomics studies to identify how an individual’s genetic make-up determines their response to drugs, including chemotherapy
  • Identify novel molecular targets for cancer therapy
  • Develop innovative cancer clinical trials and new biomarkers to predict or measure therapeutic response
  • Translate research findings into clinical application and implement new therapies, tests or tools into cancer patient care